Genmab and BliNK Biomedical have entered into a commercial license agree­ment to develop novel bispecific thera­peutics based on BliNK Biomedical’s CD47 anti­bodies and Genmab’s DuoBody® Platform tech­nology.

Copenhagen, Denmark (Press Release) – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has entered into an agree­ment with BliNK Biomedical for an exclusive commercial license to certain anti­bodies targeting CD47, for poten­tial devel­op­ment and com­mer­cial­iza­tion into novel bispecific thera­peutics created via Genmab’s pro­pri­e­tary DuoBody Platform tech­nology. This agree­ment sup­ports Genmab’s estab­lish­ed prod­uct pipe­line strategy. Under the terms of the agree­ment, Genmab will pay BliNK Biomedical an up­front fee of USD 2.25 million. BliNK Biomedical is also eli­gible to receive up to approx­i­mately USD 200 million in devel­op­ment, regu­la­tory and commercial mile­stone pay­ments for each prod­uct, as well as tiered royalties on net sales.

“With this agree­ment the scope of prod­uct concepts under devel­op­ment at Genmab has been ex­panded. CD47 has shown poten­tial as a target for cancer and we believe that a bispecific ap­proach may open up poten­tial for dif­fer­en­ti­ated ther­a­pies. We are always looking to use our in-house ex­per­tise in novel ways; we look for­ward to seeing the results from the com­bi­na­tion of Genmab’s DuoBody tech­nology with a CD47 anti­body from BliNK Biomedical,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

BliNK Biomedical is a privately-owned bio­pharma­ceu­tical com­pany based in Marseille, France, focused on discovery and devel­op­ment of thera­peutic anti­bodies in on­col­ogy and immuno-oncology.

About Genmab

Genmab is a publicly traded, inter­na­tional bio­technology com­pany specializing in the creation and devel­op­ment of dif­fer­en­ti­ated anti­body thera­peutics for the treat­ment of cancer. Founded in 1999, the com­pany has two approved anti­bodies, DARZALEX® (dara­tu­mu­mab) for the treat­ment of certain multiple myeloma indi­ca­tions, and Arzerra® (ofatumumab) for the treat­ment of certain chronic lym­pho­cytic leukemia indi­ca­tions. Dara­tu­mu­mab is in clin­i­cal devel­op­ment for addi­tional multiple myeloma indi­ca­tions, other blood cancers and amy­loid­osis. A sub­cu­tane­ous for­mu­la­tion of ofatumumab is in devel­op­ment for relapsing multiple sclerosis. Genmab also has a broad clin­i­cal and pre-clinical prod­uct pipe­line. Genmab's tech­nology base in­cludes a number of pro­pri­e­tary next generation anti­body tech­nolo­gies Genmab has alliances with other leading pharma­ceu­tical and bio­technology com­pa­nies.

Cautions Concerning Forward-Looking Statements

This Media Release con­tains for­ward looking state­ments. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar ex­pres­sions identify for­ward looking state­ments. Actual results or per­for­mance may differ ma­teri­ally from any future results or per­for­mance ex­pressed or implied by such state­ments. The im­por­tant factors that could cause our actual results or per­for­mance to differ ma­teri­ally in­clude, among others, risks asso­ci­ated with pre-clinical and clin­i­cal devel­op­ment of prod­ucts, un­cer­tain­ties related to the out­come and conduct of clin­i­cal trials in­clud­ing un­fore­seen safety issues, un­cer­tain­ties related to prod­uct manu­fac­tur­ing, the lack of mar­ket acceptance of our prod­ucts, our in­abil­ity to man­age growth, the competitive en­viron­ment in rela­tion­ to our business area and mar­kets, our in­abil­ity to attract and retain suitably qualified per­son­nel, the un­en­force­ability or lack of protection of our patents and pro­pri­e­tary rights, our rela­tion­ships with affiliated entities, changes and devel­op­ments in tech­nology which may render our prod­ucts obsolete, and other factors. For a further discussion of these risks, please refer to the risk man­agement sections in Genmab’s most recent financial reports, which are avail­able on www.genmab.com. Genmab does not under­take any obli­ga­tion to update or revise for­ward looking state­ments in this Media Release nor to con­firm such state­ments to reflect sub­se­quent events or cir­cum­stances after the date made or in rela­tion­ to actual results, unless required by law.

Genmab A/S and/or its sub­sid­i­aries own the fol­low­ing trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in com­bi­na­tion with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in com­bi­na­tion with the DuoBody logo®; HexaBody®; HexaBody in com­bi­na­tion with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Source: Genmab.